“At 1.3 µM concentration (a clinically pharmacologically achievable dose), 4HPR increased ATRA sensitivity synergistically in HER2/neu-overexpressing BT-474, MDA-MB-453, and MCF-7/Her2 breast cancer cells.”
“Combining 4HPR with ATRA may lead to a novel, selective therapeutic or chemopreventive strategy against HER2/neu-overexpressing breast tumors.”